Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

Back

ESC Professional Premium Access

Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

Session: Myocardial remodelling (1)

Topic: Cardiac Hypertrophy

Speaker: Doctor G. Milano (Lausanne, CH)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Giuseppina Milano

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

0 follower

7 more presentations in this session

  A high-throughput screening strategy identifies adenosine 5'-monophosphate as a novel enhancing molecule of the cardio-protective enzyme 5-oxoprolinase (OPLAH).

Speaker: Mr J. Esquivel Gaytan (Groningen, NL)

Melanocortin 1 receptor deficiency protects against pathological cardiac hypertrophy

Speaker: Ms A. Suominen (Turku, FI)

Betaine therapy of cardiac hypertrophy through inhibition of Hydroxy-carboxylic Acid Receptor 1 signaling

Speaker: Miss L. Yao (Nantong, CN)

ERBB4 stimulation mitigates atrial fibrillation and remodeling in a porcine DOCA model

Speaker: Doctor M. Tubeeckx (Antwerp, BE)

The anti-fibrotic effect of atrial natriuretic peptide depends on myocardial accumulation of the peptide in rat heart

Speaker: Professor S. Hatem (Paris, FR)

Access the full session

Myocardial remodelling (1)

Speakers: Doctor G. Milano, Mr J. Esquivel Gaytan, Ms A. Suominen, Miss L. Yao, Doctor M. Tubeeckx...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources